LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial.

Autor: Loesche C; Translational Medicine, Novartis BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Picard D; Translational Medicine, Novartis BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Van Hoorick B; Clinical Pharmacology Unit, SGS, Antwerp, Belgium., Schuhmann I; Biomarker Development, Novartis BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Jäger P; Immunology Disease Area, Novartis BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Klein K; PK Sciences, Novartis BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Schuhler C; Early Development Analytics, Novartis Pharma AG, Basel, Switzerland., Thoma G; Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Markert C; Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Poller B; PK Sciences, Novartis BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Zamurovic N; Preclinical Safety, Novartis BioMedical Research, Basel, Switzerland., Weiss HM; PK Sciences, Novartis BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Otto H; Immunology Disease Area, Novartis BioMedical Research, Novartis Pharma AG, Basel, Switzerland., Fink M; Early Development Analytics, Novartis Pharma AG, Basel, Switzerland., Röhn TA; Immunology Disease Area, Novartis BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Publikováno v: Clinical and translational science [Clin Transl Sci] 2024 Feb; Vol. 17 (2), pp. e13724.

In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway.

Autor: Ispasanie E; Swiss Tropical and Public Health Institute, Molecular Immunology Unit, Basel, Switzerland.; University of Basel, Basel, Switzerland., Muri L; Swiss Tropical and Public Health Institute, Molecular Immunology Unit, Basel, Switzerland.; University of Basel, Basel, Switzerland., Schmid M; Swiss Tropical and Public Health Institute, Molecular Immunology Unit, Basel, Switzerland.; University of Basel, Basel, Switzerland., Schubart A; Novartis Institutes for Biomedical Research, Department Autoimmunity, Transplantation and Inflammation, Basel, Switzerland., Thorburn C; Novartis Pharma AG, London, United Kingdom., Zamurovic N; Novartis Institutes for Biomedical Research, Translational Medicine-Preclinical Safety, Basel, Switzerland., Holbro T; Global Drug Development, Novartis Pharma AG, Basel, Switzerland., Kammüller M; Novartis Institutes for Biomedical Research, Translational Medicine-Preclinical Safety, Basel, Switzerland., Pluschke G; Swiss Tropical and Public Health Institute, Molecular Immunology Unit, Basel, Switzerland.; University of Basel, Basel, Switzerland.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Jun 29; Vol. 14, pp. 1180833. Date of Electronic Publication: 2023 Jun 29 (Print Publication: 2023).

Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals.

Autor: Muri L; Molecular Immunology Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland.; University of Basel, Basel, Switzerland., Ispasanie E; Molecular Immunology Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland.; University of Basel, Basel, Switzerland., Schubart A; Translational Medicine-Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland., Thorburn C; Novartis Pharma AG, Global Drug Development, London, United Kingdom., Zamurovic N; Translational Medicine-Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland., Holbro T; Novartis Pharma AG, Global Drug Development, Basel, Switzerland., Kammüller M; Translational Medicine-Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland., Pluschke G; Molecular Immunology Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland.; University of Basel, Basel, Switzerland.

Publikováno v: Frontiers in immunology [Front Immunol] 2021 Oct 11; Vol. 12, pp. 732146. Date of Electronic Publication: 2021 Oct 11 (Print Publication: 2021).

"A Friend Among Strangers" or the Ambiguous Roles of Runx2.

Autor: Azarkina, Kseniia¹ (AUTHOR), Gromova, Ekaterina¹ (AUTHOR), Malashicheva, Anna¹ (AUTHOR) malashicheval@incras.ru

Publikováno v: Biomolecules (2218-273X). Nov2024, Vol. 14 Issue 11, p1392. 17p.

Malt1 Protease Deficiency in Mice Disrupts Immune Homeostasis at Environmental Barriers and Drives Systemic T Cell-Mediated Autoimmunity.

Autor: Martin K; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Touil R; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Kolb Y; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Cvijetic G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Murakami K; The Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada., Israel L; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Duraes F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Buffet D; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Glück A; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Niwa S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Bigaud M; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Junt T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Zamurovic N; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Smith P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., McCoy KD; Department of Clinical Research, University Clinic for Visceral Surgery and Medicine, University Hospital, 3010 Bern, Switzerland; and., Ohashi PS; The Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.; Department of Immunology, University of Toronto, Toronto, Ontario M5G 2C1, Canada., Bornancin F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland., Calzascia T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland; thomas.calzascia@novartis.com.

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2019 Dec 01; Vol. 203 (11), pp. 2791-2806. Date of Electronic Publication: 2019 Oct 28.